Resverlogix Corp.  

(Public, TSE:RVX)   Watch this stock  
Find more results for RVX
+0.030 (5.36%)
Nov 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.56 - 0.59
52 week 0.44 - 0.89
Open 0.57
Vol / Avg. 45,105.00/18,465.00
Mkt cap 50.15M
P/E 2.38
Div/yield     -
EPS 0.25
Shares 85.31M
Beta 3.07
Inst. own     -
Dec 2, 2014
Resverlogix Corp at LD Micro Conference - 7:00PM EST - Add to calendar
Nov 4, 2014
Resverlogix Corp at EBD Group BIO-Europe Conference
Sep 10, 2014
Resverlogix Corp at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Jul '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 794.04% 468.53%
Return on average equity - -
Employees 19 -
CDP Score - -


Suite 202, 279 Midpark Way SE
+1-403-2549252 (Phone)
+1-403-2568495 (Fax)

Website links


Resverlogix Corp. is a Canada-based, clinical stage cardiovascular company. The Company has pigenetic platform technology that modulates protein production. The Company is engaged in developing RVX-208, a small molecule for the treatment of atherosclerosis. RVX-208 is a first bromodomain and extra terminal domain (BET) inhibitor in clinical trials. New compounds arising from the Company's epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases, including neurodegenerative diseases and diabetes mellitus. Its clinical cardiovascular programs include cardiovascular disease and atherosclerosis, Apoa-I, HDL and reverse cholesterol transport, and RVX-208 and MOA.

Officers and directors

Peter Johann Ph.D. Independent Chairman of the Board
Donald J. McCaffrey President, Chief Executive Officer, Secretary, Director
A. Brad Cann CA Chief Financial Officer
Jan O. Johansson M.D., Ph.D. Senior Vice President - Medical Affairs
Kenneth Lebioda Senior Vice President - Business & Corporate Development
Michael T. Sweeney M.D. Senior Vice President - Clinical Development
Norman Wong M.D. Chief Scientific Officer
Kelly B. McNeill Independent Director
Eldon R. Smith M.D. Independent Director
Age: 74
Kenneth J. Zuerblis Independent Director
Age: 55